Oncology · ChemotherapyRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Zydus' Methotrexate Sodium Supplement

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Zydus Pharmaceuticals9 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 6:31:58 PM

Assessment confidence: 52% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of Zydus' supplemental application for Methotrexate Sodium is significant as it strengthens Zydus' competitive position in the oncology market. Pharma strategy teams should evaluate the implications for market share and potential responses from other Methotrexate manufacturers. Regulatory context from FDA (FDA AP — METHOTREXATE SODIUM (ORIG)) supports the near-term read. Assessment grounded in 26 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on Zydus' market share and consider potential competitive responses from other manufacturers of Methotrexate. The strongest clinical anchor is Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 7 regulatory and 4 competitive items passed relevance filtering for Zydus Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Datopotamab Deruxtecan Supplement (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Grants Priority Review for Tecentriq Hybreza Supplement Application. This approval may enhance Zydus' position in the oncology market, particularly in the chemotherapy segment where Methotrexate is a key agent.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHOTREXATE SODIUM (ORIG) (FDA). Entity match (methotrexate sodium). The approval status indicates compliance with FDA standards, but ongoing monitoring is necessary for any changes in launch timelines or regulatory requirements.

Key Risks

Elevated medium regulatory exposure for Zydus Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Zydus' enhanced position may lead to increased market share in the chemotherapy segment, impacting revenue dynamics among competitors.
Upside for Zydus Pharmaceuticals may improve if Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Zydus Pharmaceuticals may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on Zydus' market share and consider potential competitive responses from other manufacturers of Methotrexate.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the launch timeline and any competitive reactions from other Methotrexate suppliers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium)
FDA document
View source
FDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Datopotamab Deruxtecan Supplement
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Tecentriq Hybreza Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Tecentriq Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for ENHERTU Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Zydus Pharmaceuticals
Methotrexate Sodium

Commercial impact

medium

Zydus' enhanced position may lead to increased market share in the chemotherapy segment, impacting revenue dynamics among competitors.

Regulatory impact

medium

The approval status indicates compliance with FDA standards, but ongoing monitoring is necessary for any changes in launch timelines or regulatory requirements.

What to watch

Monitor for further updates on the launch timeline and any competitive reactions from other Methotrexate suppliers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.